Future Optimal Research and Care Evaluation
FORCE-ACS
1 other identifier
observational
99,999
1 country
4
Brief Summary
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed. Current guidelines are mainly based on well controlled RCT's, though evaluation of the impact of such RCT's in the real world is missing. In order to evaluate the impact and to overcome certain limitations of RCT's, a more practical approach is required. In this sense the use of nonrandomized observational studies is an important tool for determining the effectiveness of a therapy in routine clinical practice. One way to gain insight in characteristics of patients presenting in daily clinical practice, is to simply register these characteristics in a prospective manner with adequate follow up. Objective: To create an ongoing registry for evaluation of clinical long-term impact of diagnostics, various treatments and devices used for ACS, for research and evaluation of quality of care and to evaluate and improve regional quality of care and cooperation between PCI and non-PCI centers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2015
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 25, 2019
CompletedFirst Posted
Study publicly available on registry
January 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2050
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2050
January 30, 2019
January 1, 2019
35.5 years
January 25, 2019
January 29, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants with
* All-cause mortality * Myocardial infarction * Stent thrombosis * Stroke * Revascularisation * All bleeding requiring medical evaluation
3 years
Secondary Outcomes (1)
Number of participants with
3 years
Eligibility Criteria
All patients admitted to the hospital ward with acute coronary syndrome or symptoms suggestive for acute coronary syndrome are invited to participate in the registry.
You may qualify if:
- All patients presenting with ACS
- Age ≥ 18 years
You may not qualify if:
- No oral or signed informed consent available.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- J.M. ten Berglead
- Vereniging Hart-Betercollaborator
- St. Antonius Hospitalcollaborator
- ZonMw: The Netherlands Organisation for Health Research and Developmentcollaborator
- AstraZenecacollaborator
Study Sites (4)
Gelre Ziekenhuizem
Apeldoorn, Gelderland, 7334 DZ, Netherlands
Rijnstate Arnhem
Arnhem, Gelderland, 6815 AD, Netherlands
Gelderse Vallei
Ede, Gelderland, 6716 RP, Netherlands
Ziekenhuis Rivierenland
Tiel, Gelderland, 4002 WP, Netherlands
Related Publications (3)
van den Broek WWA, Azzahhafi J, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, Dijksman LM, Walhout RJ, Tjon Joe Gin M, Breet NJ, Langerveld J, Vlachojannis GJ, van Bommel RJ, Appelman Y, van Schaik RHN, Henriques JPS, Kikkert WJ, Ten Berg JM. Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome. Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):230-240. doi: 10.1093/ehjcvp/pvae087.
PMID: 39537191DERIVEDvan der Sangen NMR, Azzahhafi J, Chan Pin Yin DRPP, Peper J, Rayhi S, Walhout RJ, Tjon Joe Gin M, Nicastia DM, Langerveld J, Vlachojannis GJ, van Bommel RJ, Appelman Y, Henriques JPS, Ten Berg JM, Kikkert WJ. External validation of the GRACE risk score and the risk-treatment paradox in patients with acute coronary syndrome. Open Heart. 2022 Mar;9(1):e001984. doi: 10.1136/openhrt-2022-001984.
PMID: 35354660DERIVEDChan Pin Yin DRPP, Vos GA, van der Sangen NMR, Walhout R, Tjon Joe Gin RM, Nicastia DM, Langerveld J, Claassens DMF, Gimbel ME, Azzahhafi J, Bor WL, Oirbans T, Dekker J, Vlachojannis GJ, van Bommel RJ, Appelman Y, Henriques JPS, Kikkert WJ, Ten Berg JM. Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice. J Clin Med. 2020 Sep 30;9(10):3173. doi: 10.3390/jcm9103173.
PMID: 33007932DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Johan Dekker, Drs.
St. Antonius Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principle investigator
Study Record Dates
First Submitted
January 25, 2019
First Posted
January 30, 2019
Study Start
January 1, 2015
Primary Completion (Estimated)
June 30, 2050
Study Completion (Estimated)
June 30, 2050
Last Updated
January 30, 2019
Record last verified: 2019-01